Table 2.
Clinical profiles of the patients of COVID-19 receiving immune therapy
| Variables | Total (n = 199) | Discharged (n = 122) | Expired (n = 77) | Difference (95% CI) | p-value |
|---|---|---|---|---|---|
| Characteristics of patients | |||||
| Age, median (IQR) (years) | 64.0 (53.0-70.0) | 60.0 (50.0-67.0) | 58.0 (52.0-62.0) | 6.4 (3.25-9.62) | <0.001 |
| Age group | |||||
| 18-50 - no. (%) | 40 (20) | 31 (25) | 9 (21) | <0.05 | |
| 51-70 -no. (%) | 117 (59) | 69 (57) | 48 (74) | 0.417 | |
| ≥71 - no. (%) | 42 (21) | 22 (18) | 20 (26) | 0.180 | |
| Female - no. (%) | 41 (21) | 25 (20) | 16 (21) | 0.960 | |
| Male - no. (%) | 158 (79) | 97 (80) | 61 (79) | 0.960 | |
| Preexisting conditions | |||||
| Hypertension - no. (%) | 155 (78) | 98 (80) | 57 (74) | 0.298 | |
| Diabetes mellitus - no. (%) | 19 (10) | 13 (11) | 6 (8) | 0.502 | |
| Asthma - no. (%) | 2 (1) | - | 2 (3) | ||
| Chronic kidney disease - no. (%) | 7 (4) | 4 (3) | 3 (4) | 0.818 | |
| Presenting symptoms | |||||
| Pneumonia - no. (%) | 199 (100) | 122 (100) | 77 (100) | 1.000 | |
| Multiple organ dysfunction syndrome - no. (%) | 199 (100) | 122 (100) | 77 (100) | 1.000 | |
| Coagulopathy - no. (%) | 199 (100) | 122 (110) | 77 (100) | 1.000 | |
| Percentage of lung involvement analyzed by HRCT, median (IQR) | 65 (58-76) | 58 (52-64) | 74 (64-78) | 11.1 (8.0-14.1) | <0.001 |
| > 50% - no. (%) | 121 (61) | 65 (53) | 56 (73) | ||
| Oxygen saturation, median (IQR) | 83 (82-86) | 84 (82-88) | 83 (81-84) | 2.3 (1.4-3.1) | <0.001 |
The values of presenting symptoms just before the commencement of immune therapy have been cited; CI, confidence interval; IQR, interquartile range